BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
May 07, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
May 07, 2024 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn...
L’écosystème de la biofabrication du Canada propulsé grâce à un nouveau financement
May 06, 2024 12:02 ET
|
Fondation canadienne pour l’innovation
MONTRÉAL, 06 mai 2024 (GLOBE NEWSWIRE) -- La Fondation canadienne pour l’innovation (FCI) aide les établissements du pays à se préparer à faire face aux pandémies et à d’autres urgences...
Canada’s biomanufacturing ecosystem gets major boost with new funding
May 06, 2024 12:02 ET
|
Canada Foundation for Innovation
MONTREAL, May 06, 2024 (GLOBE NEWSWIRE) -- The Canada Foundation for Innovation (CFI) is helping the country’s institutions prepare for pandemics and other health emergencies though its Biosciences...
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
May 06, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
May 03, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
May 02, 2024 07:15 ET
|
Ocugen
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...